Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share.
The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on 18 December 2015 purchased 750,000 Ordinary Shares at 6.75 pence per Ordinary Share.
Following the above transactions, Michael Sinclair now holds 90,079,757 Ordinary Shares representing 6.35% of the issued share capital of the Company and Michael Bradfield now holds 124,518,510 Ordinary Shares representing 8.78% of the issued share capital of the Company.
.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Beaufort Securities (Joint Broker) |
|
|
Jon Levinson / Elliot Hance |
Tel: +44 20 7382 8300 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy Brand Communications Alan Green |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 Tel: +44 1273 704473 Mob: +44 7976 431608 |